#1 Clinical Trials Search in Europe

Gebasaxturev

This article discusses the use of gebasaxturev, an investigational drug, in clinical trials for the treatment of stage III melanoma. The trials aim to evaluate the safety, efficacy, and potential benefits of gebasaxturev in combination with other treatments for patients with advanced melanoma who are candidates for neoadjuvant therapy. Understanding these trials can provide valuable insights into potential new treatment options for melanoma patients.

Table of Contents

What is GEBASAXTUREV?

GEBASAXTUREV, also known as CVA21 or Coxsackievirus A21, is an investigational biological treatment being studied for advanced melanoma[1]. It is a solution for injection that is administered directly into tumors (intratumoral use). This innovative therapy is part of a class of treatments called oncolytic viruses, which are designed to target and destroy cancer cells while sparing healthy tissue.

Medical Condition Treated

GEBASAXTUREV is being investigated for the treatment of Stage IIIB, IIIC, or IIID melanoma[1]. Melanoma is a type of skin cancer that develops in the cells responsible for producing melanin, the pigment that gives skin its color. Stage III melanoma indicates that the cancer has spread beyond the original site to nearby lymph nodes or tissues, but has not yet reached distant parts of the body.

How GEBASAXTUREV is Used

GEBASAXTUREV is administered as a solution for injection directly into the tumor[1]. This method, known as intratumoral injection, allows the treatment to be delivered precisely to the cancer cells. The therapy is being studied as part of a combination treatment approach, which may include other medications such as pembrolizumab, an immunotherapy drug.

Clinical Trial Objectives

The ongoing clinical trial aims to evaluate several aspects of GEBASAXTUREV treatment[1]:

  1. Safety and tolerability of the treatment combination
  2. Effectiveness in achieving a pathological complete response (pCR), which means no detectable cancer cells remain after treatment
  3. Rate of near pathological complete response (near pCR) and pathological partial response (pPR)
  4. Impact on recurrence-free survival (RFS), or how long patients remain cancer-free after treatment

Eligibility Criteria

To participate in the clinical trial for GEBASAXTUREV, patients must meet specific criteria[1]. Some key inclusion criteria are:

  • Confirmed diagnosis of melanoma
  • Stage IIIB, IIIC, or IIID melanoma that can be surgically removed
  • No prior treatment for Stage III melanoma (except for surgical removal of primary melanoma or radiotherapy to the primary site)
  • Adequate organ function

Exclusion criteria include:

  • History of immunodeficiency or active autoimmune disease
  • Recent systemic anticancer therapy or major surgery
  • Known central nervous system metastases
  • Ocular or mucosal melanoma

Safety Considerations

As with any investigational treatment, there are important safety considerations for patients considering GEBASAXTUREV[1]:

  • The trial monitors for adverse events (AEs) and treatment discontinuations due to AEs
  • Patients with a history of pneumonitis, active tuberculosis, or certain infections are excluded from the trial
  • Special precautions are taken for patients with potential exposure to live vaccines or those with a history of organ transplants
  • Male and female participants must agree to use effective contraception during the treatment period and for a specified time afterward

It’s important to note that GEBASAXTUREV is still under investigation, and its full safety profile and effectiveness are yet to be determined. Patients interested in this treatment should discuss their options with their healthcare provider and consider participation in clinical trials if appropriate for their situation.

Aspect Details
Drug Name Gebasaxturev (CVA21, Coxsackievirus A21)
Trial Phase Phase 1/2
Target Condition Stage IIIB, IIIC, or IIID melanoma
Administration Intratumoral injection
Primary Objectives Safety, tolerability, pathological complete response rate
Secondary Objectives Near pathological complete response rate, pathological partial response rate, recurrence-free survival
Key Inclusion Criteria Confirmed melanoma, untreated stage III, adequate organ function
Key Exclusion Criteria Immunodeficiency, active infections, prior systemic anticancer therapy within 4 weeks

FAQ

  • What is gebasaxturev? Gebasaxturev is an investigational drug being studied for the treatment of stage III melanoma. It is also known as CVA21 or Coxsackievirus A21 and is classified as a biological product.
  • What type of melanoma is being studied in this trial? The trial focuses on patients with stage IIIB, IIIC, or IIID melanoma that is clinically detectable, resectable, and amenable to surgery.
  • How is gebasaxturev administered in the trial? Gebasaxturev is administered as a solution for injection through intratumoral use, which means it is injected directly into the tumor.
  • What are the main objectives of the clinical trial? The main objectives are to assess the safety and tolerability of the treatment combinations, evaluate the pathological complete response rate, and study other measures such as near pathological complete response rate and recurrence-free survival.
  • Who is eligible to participate in this clinical trial? Eligible participants include those with confirmed stage IIIB, IIIC, or IIID melanoma that is untreated (except for primary tumor removal), have adequate organ function, and meet specific criteria regarding contraception use and absence of certain medical conditions.

Ongoing Clinical Trials on Gebasaxturev

  • Study on the Safety and Effectiveness of Pembrolizumab and Drug Combination for Patients with Stage III Melanoma Eligible for Neoadjuvant Therapy

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Italy

Glossary

  • Melanoma: A type of skin cancer that develops in cells called melanocytes, which produce the pigment that gives skin its color.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Pathological complete response (pCR): The absence of all signs of cancer in tissue samples removed during surgery or biopsy after treatment.
  • Recurrence-free survival (RFS): The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer.
  • Intratumoral use: Administration of a drug directly into a tumor.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Immunodeficiency: A state in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent.
  • Allogeneic transplant: A procedure in which a person receives stem cells or tissue from a genetically similar, but not identical, donor.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-pembrolizumab-and-drug-combination-for-patients-with-stage-iii-melanoma-eligible-for-neoadjuvant-therapy/